Jazz Pharmaceuticals plc

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-14 pm EST			5-day change	1st Jan Change
122.96 ^USD	-0.16%		+0.94%	-0.15%

06:45pm	Jazz Pharmaceuticals plc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 09:45 AM
Jan. 08	Zymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027	MT

Sector Update: Health Care Stocks Rise Pre-Bell Thursday

November 21, 2024 at 09:14 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 09:45 AM	12:45pm
Zymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027	Jan. 08	MT
Akari Therapeutics, plc Announces Board Changes	Dec. 18	CI
Jazz Pharmaceuticals CEO Bruce Cozadd Plans to Retire	Dec. 16	MT
Jazz Pharmaceuticals 'On Track to Meet its Full Year 2024 Revenue Guidance' of $4.0-$4.1 Billion	Dec. 16	MT
Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025	Dec. 16	CI
Truist Securities Adjusts Jazz Pharmaceuticals Public Price Target to $220 From $200, Maintains Buy Rating	Dec. 16	MT
Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, $175 Price Target	Dec. 12	MT
Jazz Pharmaceuticals plc - Special Call	Dec. 11
Jazz Pharmaceuticals Likely to Launch FDA-Approved Biliary Tract Cancer Treatment in 2025, RBC Says	Dec. 10	MT
Alx Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer	Dec. 10	CI
Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits	Dec. 06	CI
Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?)	Dec. 05	CI
Jazz Pharmaceuticals plc Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 10:15 AM	Dec. 03
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting	Dec. 03	CI
Roche: companion diagnostic test approved in the USA	Nov. 25	CF
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA	Nov. 25	CI
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK	Nov. 21	DJ
Sector Update: Health Care Stocks Rise Pre-Bell Thursday	Nov. 21	MT
Sector Update: Health Care	Nov. 21	MT
Nvidia Earnings in Focus as US Equity Futures Post Narrow Gains Pre-Bell	Nov. 21	MT
Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer	Nov. 21	MT
Jazz Pharmaceuticals Receives US FDA Accelerated Approval for Biliary Tract Cancer Treatment	Nov. 21	MT
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer	Nov. 20	CI
UBS Raises Price Target on Jazz Pharmaceuticals Public to $128 From $121, Maintains Neutral Rating	Nov. 19	MT

Chart Jazz Pharmaceuticals plc

Duration

Period

JAZZ: Dynamic Chart

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Employees

2,800

Sector

Pharmaceuticals

Calendar

12:45pm - JP Morgan Healthcare Conference

More about the company